Company overview
USCC
914404005573482907
Id2
440400000235288
English Name
Livzon Mabpharm Inc.
Former names
-
Chinese Name
珠海市丽珠单抗生物技术有限公司
Entity type
Limited Liability Company (Wholly Foreign-Owned Enterprise)
Authorized capital
¥145,333
Phone
+867567238688
Representative
朱保国
Establishment date
2 July 2010
Country
China
Primary goods traded
| Data Source | HS Code | Description | Buyer | Buyer Country | Seller | Seller Country | ||
|---|---|---|---|---|---|---|---|---|
| 5 August 2021 | ID | 30021500 | Tocilizumab Injection (Recombinant Humanized Anti-Human) Il-6r Monoclonal Antibody Solution | PT Perusahaan Perseroan Persero PT Kimia Farma | ID | Livzon Mabpharm Inc | CN | $1,181,684.15 |
| 6 August 2021 | ID | 30021500 | Tocilizumab Injection (Recombinant Humanized Anti-Human) Il-6r Monoclonal Antibody Solution | PT Perusahaan Perseroan Persero PT Kimia Farma | ID | Livzon Mabpharm Inc | CN | $1,137,102.00 |
| 15 October 2024 | ID | 30043900 | Infertreat | PT Lapi Laboratories | ID | Livzon Mabpharm Inc | $241,310.65 | |
| 26 December 2023 | ID | 30043900 | Infertreat | PT Lapi Laboratories | ID | Livzon Mabpharm Inc | $237,530.63 |
| Partner | Type | Total Value | Percentage |
|---|---|---|---|
| PT Kimia Farma | buyer | $2,318,786 | 82.88% |
| PT Lapi Laboratories | buyer | $478,841 | 17.12% |